Premium
Tumor hormone receptor status and recurrences in premenopausal patients with node‐negative breast carcinoma
Author(s) -
Tsangaris Theodore N.,
Knox Sally M.,
Cheek J. Harold
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920215)69:4<984::aid-cncr2820690425>3.0.co;2-c
Subject(s) - medicine , breast cancer , breast carcinoma , estrogen receptor , oncology , cancer , hormone receptor , hormone , gynecology , disease , carcinoma , estrogen
To ascertain the prognostic significance of tumor hormone receptor status in premenopausal patients with node‐negative breast cancer, a retrospective review of 199 patients who met these criteria was conducted. Of these 199 patients, estrogen receptor (ER) data were available for 147. One hundred four patients (71%) had ER‐negative disease and 22 (21%) exhibited local or distant recurrence with a median follow‐up time of 85.4 months. Thirteen patients in this group had died of breast cancer. Of the 43 patients who had ER‐positive disease, 5 (12%) had recurrences and 2 died of breast cancer. After observing patients for a longer period of time (median follow‐up time, 85.4 months), no statistically significant differences in disease‐free survival (DFS) or overall survival (OS) were demonstrated. However, as seen in our first analysis of this group at 45 months, tumor size after a median follow‐up time of 85.4 months continues to have significant prognostic implications, regardless of ER status. Cancer 1992; 69:984–987.